Ginkgo Bioworks Holdings, Inc.

NYSE DNA

Ginkgo Bioworks Holdings, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -0.76

Ginkgo Bioworks Holdings, Inc. Price to Earnings Ratio (P/E) is -0.76 on January 14, 2025, a 74.93% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Ginkgo Bioworks Holdings, Inc. 52-week high Price to Earnings Ratio (P/E) is -0.34 on September 09, 2024, which is 55.33% above the current Price to Earnings Ratio (P/E).
  • Ginkgo Bioworks Holdings, Inc. 52-week low Price to Earnings Ratio (P/E) is -3.83 on February 15, 2024, which is -406.72% below the current Price to Earnings Ratio (P/E).
  • Ginkgo Bioworks Holdings, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.52.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
NYSE: DNA

Ginkgo Bioworks Holdings, Inc.

CEO Dr. Jason Kelly Ph.D.
IPO Date April 19, 2021
Location United States
Headquarters 27 Drydock Avenue
Employees 1,218
Sector Health Care
Industries
Biotechnology
Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

StockViz Staff

January 15, 2025

Any question? Send us an email